GDC-0449 and Sonidegib have received approval from the Food and Drug Administration to treat cancer, but like other targeted cancer medicines, these two Smo inhibitors have caused tumor relapse, primarily attributable to acquired resistance to Smo and the activation of the Hh non-classical pathway [31, 32]. This evidence concerns the gene SMO and cancer.